JP2011527899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527899A5 JP2011527899A5 JP2011518016A JP2011518016A JP2011527899A5 JP 2011527899 A5 JP2011527899 A5 JP 2011527899A5 JP 2011518016 A JP2011518016 A JP 2011518016A JP 2011518016 A JP2011518016 A JP 2011518016A JP 2011527899 A5 JP2011527899 A5 JP 2011527899A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- hcmv
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 22
- 108090001123 antibodies Proteins 0.000 claims 22
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 6
- 102000038129 antigens Human genes 0.000 claims 6
- 108091007172 antigens Proteins 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 201000009910 diseases by infectious agent Diseases 0.000 claims 4
- 101710042049 UL131A Proteins 0.000 claims 3
- 230000035693 Fab Effects 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 210000002889 Endothelial Cells Anatomy 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003472 neutralizing Effects 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
Claims (15)
- ｈＣＭＶタンパク質ＵＬ１２８、ＵＬ１３０、およびＵＬ１３１Ａの組み合わせに特異的であり、ヒトサイトメガロウイルス（ｈＣＭＶ）による内皮細胞、網膜細胞、または樹状細胞の感染を中和する、単離された抗体またはその抗原結合断片であって、ｈＣＭＶを５０％中和するのに必要とされる前記抗体の濃度は、０．１μｇ／ｍＬ以下である、前記単離された抗体またはその抗原結合断片。
- 前記３つのタンパク質によって形成される立体構造エピトープに結合する、請求項１に記載の抗体または断片。
- 配列番号１、配列番号２、および配列番号３にそれぞれ記載される、ＣＤＲ１、ＣＤＲ２、およびＣＤＲ３重鎖可変領域配列、または配列番号４、配列番号５、および配列番号６にそれぞれ記載される、ＣＤＲ１、ＣＤＲ２、および／もしくはＣＤＲ３軽鎖可変領域配列を含む、ｈＣＭＶタンパク質ＵＬ１２８、ＵＬ１３０、およびＵＬ１３１Ａの組み合わせに特異的な、単離された抗体またはその抗原結合断片。
- 配列番号７に記載される重鎖可変領域、および／または配列番号８に記載される軽鎖可変領域を含む、ｈＣＭＶタンパク質ＵＬ１２８、ＵＬ１３０、およびＵＬ１３１Ａの組み合わせに特異的な、単離された抗体またはその抗原結合断片。
- 前記抗体は、ヒト抗体、モノクローナル抗体、ヒトモノクローナル抗体、単鎖抗体、Ｆａｂ、Ｆａｂ'、Ｆ（ａｂ'）２、Ｆｖ、またはｓｃＦｖである、請求項１〜４のうちのいずれか１項に記載の抗体または断片。
- ｈＣＭＶ感染を中和し、請求項４に記載の抗体または断片と同じエピトープに結合するか、またはｈＣＭＶへの結合に対して請求項４に記載の抗体または断片と競合する、単離された抗体またはその抗原結合断片。
- 請求項３〜５のうちのいずれか１項に記載の抗体または断片をコードするヌクレオチド配列を含む、単離された核酸分子。
- 配列番号９、１０、１１、１２、１３、１４、１５、または１６のうちのいずれか１つと少なくとも９５％同一であるヌクレオチド配列を含む、請求項７に記載の核酸分子。
- 請求項７または８に記載の核酸分子を含む、ベクター。
- 請求項９に記載のベクターを含む、細胞。
- 請求項１〜６のうちのいずれか１項に記載の抗体または断片を発現する、単離された細胞。
- 請求項１〜６のうちのいずれか１項に記載の抗体もしくは断片、または請求項７もしくは８に記載の核酸、および薬学的に許容される希釈剤もしくは担体、ならびに任意で第２の抗体もしくはその抗原結合断片を含む、ｈＣＭＶ感染を中和する組成物。
- 第２の抗体が、gBタンパク質に結合する、請求項12記載の組成物。
- ｈＣＭＶ感染の治療用の薬物の製造における、請求項１〜６のうちのいずれか１項に記載の抗体もしくは断片、請求項７もしくは８に記載の核酸、または請求項１０に記載の細胞の使用。
- 請求項１〜６のうちのいずれか１項に記載の抗体または断片を産生するための方法であって、
（ｉ）請求項１０に記載の細胞を培養すること、および（ｉｉ）前記抗体または断片を単離することを含む、前記方法。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2008/002683 WO2010007463A1 (en) | 2008-07-16 | 2008-07-16 | Human cytomegalovirus neutralising antibodies and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013248834A Division JP2014087349A (ja) | 2013-12-02 | 2013-12-02 | ヒトサイトメガロウイルス中和抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527899A JP2011527899A (ja) | 2011-11-10 |
| JP2011527899A5 true JP2011527899A5 (ja) | 2012-05-17 |
| JP5475774B2 JP5475774B2 (ja) | 2014-04-16 |
Family
ID=40430130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518016A Expired - Fee Related JP5475774B2 (ja) | 2008-07-16 | 2008-07-16 | ヒトサイトメガロウイルス中和抗体およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP2960250A1 (ja) |
| JP (1) | JP5475774B2 (ja) |
| KR (3) | KR20140041951A (ja) |
| CN (1) | CN102143974B (ja) |
| AU (1) | AU2008359583B2 (ja) |
| BR (1) | BRPI0822989A2 (ja) |
| CA (1) | CA2730620A1 (ja) |
| EA (1) | EA201170204A1 (ja) |
| ES (1) | ES2548014T3 (ja) |
| IL (1) | IL210352A0 (ja) |
| MA (1) | MA32566B1 (ja) |
| MX (1) | MX2011000542A (ja) |
| NZ (1) | NZ591055A (ja) |
| PT (1) | PT2303923E (ja) |
| TN (1) | TN2010000616A1 (ja) |
| WO (1) | WO2010007463A1 (ja) |
| ZA (1) | ZA201100489B (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| MX343490B (es) | 2008-07-16 | 2016-11-08 | Inst For Res In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos. |
| WO2011076883A1 (en) | 2009-12-23 | 2011-06-30 | 4-Antibody Ag | Binding members for human cytomegalovirus |
| JP5940064B2 (ja) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | 低用量のｒｎａを用いた大型哺乳動物の免疫化 |
| EP2590670B1 (en) | 2010-07-06 | 2017-08-23 | GlaxoSmithKline Biologicals SA | Methods of raising an immune response by delivery of rna |
| MX2013000164A (es) | 2010-07-06 | 2013-03-05 | Novartis Ag | Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn. |
| HRP20220695T1 (hr) | 2010-08-31 | 2022-07-08 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za isporuku rnk kodirane za imunogen |
| KR102162111B1 (ko) | 2010-10-11 | 2020-10-07 | 노파르티스 아게 | 항원 전달 플랫폼 |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| CN102286099B (zh) * | 2011-08-05 | 2014-04-09 | 深圳市卫光生物制品股份有限公司 | 静注巨细胞病毒人免疫球蛋白及其制备方法 |
| CN104321444A (zh) * | 2012-03-27 | 2015-01-28 | 变异生物技术公司 | 用于检测抗巨细胞病毒中和抗体的方法 |
| CN104838000B (zh) * | 2012-07-27 | 2022-12-20 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
| WO2014099908A1 (en) * | 2012-12-17 | 2014-06-26 | Genentech, Inc. | Methods for inhibiting viral infection in transplant patients |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CN107325178A (zh) * | 2017-06-29 | 2017-11-07 | 佛山市南海区普罗圣塔生物科技有限公司 | 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用 |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| KR20230141840A (ko) * | 2021-02-05 | 2023-10-10 | 암젠 인크 | 비종말적 항체 발굴 방법 및 단일 세포 분석 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0248909B1 (en) * | 1985-12-06 | 1994-08-17 | Teijin Limited | Anticytomegaloviral human monoclonal antibody and process for its preparation |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1998057993A1 (en) | 1997-06-19 | 1998-12-23 | The Regents Of The University Of California | Secretory immunoglobulin produced by single cells and methods for making and using same |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| PT2662390T (pt) * | 2004-06-21 | 2017-10-09 | Squibb & Sons Llc | Anticorpos contra recetor 1 do interferão alfa e as suas utilizações |
| EP2336174B8 (en) * | 2005-03-14 | 2015-09-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Human monoclonal antibodies against Hendra and Nipah viruses |
| EP2037959B1 (en) * | 2006-06-07 | 2016-01-27 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| GB0700133D0 (en) * | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
-
2008
- 2008-07-16 MX MX2011000542A patent/MX2011000542A/es active IP Right Grant
- 2008-07-16 KR KR1020147006967A patent/KR20140041951A/ko not_active Application Discontinuation
- 2008-07-16 EP EP15172997.7A patent/EP2960250A1/en not_active Withdrawn
- 2008-07-16 EA EA201170204A patent/EA201170204A1/ru unknown
- 2008-07-16 PT PT88757083T patent/PT2303923E/pt unknown
- 2008-07-16 CA CA2730620A patent/CA2730620A1/en not_active Abandoned
- 2008-07-16 KR KR1020117001329A patent/KR101407216B1/ko active IP Right Grant
- 2008-07-16 EP EP08875708.3A patent/EP2303923B1/en active Active
- 2008-07-16 JP JP2011518016A patent/JP5475774B2/ja not_active Expired - Fee Related
- 2008-07-16 AU AU2008359583A patent/AU2008359583B2/en not_active Ceased
- 2008-07-16 ES ES08875708.3T patent/ES2548014T3/es active Active
- 2008-07-16 BR BRPI0822989A patent/BRPI0822989A2/pt not_active IP Right Cessation
- 2008-07-16 CN CN200880130982.9A patent/CN102143974B/zh not_active Expired - Fee Related
- 2008-07-16 NZ NZ591055A patent/NZ591055A/xx not_active IP Right Cessation
- 2008-07-16 KR KR20147033802A patent/KR20150002895A/ko not_active Application Discontinuation
- 2008-07-16 WO PCT/IB2008/002683 patent/WO2010007463A1/en active Application Filing
-
2010
- 2010-12-28 TN TNP2010000616A patent/TN2010000616A1/fr unknown
- 2010-12-29 IL IL210352A patent/IL210352A0/en unknown
-
2011
- 2011-01-19 ZA ZA2011/00489A patent/ZA201100489B/en unknown
- 2011-02-15 MA MA33620A patent/MA32566B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527899A5 (ja) | ||
| JP2011527902A5 (ja) | ||
| JP2024038003A5 (ja) | ||
| JP2022177090A5 (ja) | ||
| JP2018521638A5 (ja) | ||
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| JP2019527553A5 (ja) | ||
| JP2010516229A5 (ja) | ||
| JP2020535799A5 (ja) | ||
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| JP2012525829A5 (ja) | ||
| JP2016529882A5 (ja) | ||
| JP2012501669A5 (ja) | ||
| JP2014526898A5 (ja) | ||
| JP2012143232A5 (ja) | ||
| JP2015535828A5 (ja) | ||
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2013506428A5 (ja) | ||
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| JP2016516400A5 (ja) | ||
| JP2015511817A5 (ja) | ||
| JP2009225799A5 (ja) | ||
| JP2012501670A5 (ja) | ||
| JP2011509245A5 (ja) | ||
| JP2012254092A5 (ja) |